Skip to content

Metabolic Effects of Stevia in Type 2 Diabetic Patients

Effects of Stevia on Glycaemic Profile and Insulin Secretion of Type 2 Diabetic Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02834715
Acronym
STEDIA1
Enrollment
22
Registered
2016-07-15
Start date
2016-03-31
Completion date
2016-08-31
Last updated
2017-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Diabetes, Stevia, insulin secretion, insulin sensitivity, Sweetener

Brief summary

The main aim of the study is to assess the short term and 1-month metabolic effects of Stevia rebaudiana bertoni in patients with type 2 diabetes.

Detailed description

This is a non-randomized clinical trial in a type 2 diabetic population aiming to investigate the effect of Stevia rebaudiana bertoni on the glycaemic and insulin secretory response to a mixed meal tolerance test, insulin sensitivity and lipid profile. The study has two arms including an intervention arm (test group) and a non-intervention arm (controls) matched for age, sex and body mass index in 2:1 ratio. The intervention is made of two phases including 1. A mixed meal tolerance test with and without 240 mg of Stevia in a randomized order to evaluate the acute effects; 2. An oral intake of 240 mg of Stevia within 30 days as food supplement in order to assess medium-term effects

Interventions

DIETARY_SUPPLEMENTStevia rebaudiana liquid extract

Sweetener made of liquid stevia self administered daily for 30 days

Sponsors

Yaounde Central Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
21 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Known type 2 diabetes * Unchanged hypoglycaemic treatment for at least 3 months prior to inclusion * No acute complication of diabetes * HbA1C≤ 8%

Exclusion criteria

* Infection up to 10 days prior to inclusion * Serum ALAT \>3N, * MDRD estimated creatinine clearance \<60ml/min * Tobacco smoking

Design outcomes

Primary

MeasureTime frameDescription
Glycaemic profile in response to mixed meal test1 monthChange in blood glucose profile during a mixed meal test at baseline and after one month intervention

Secondary

MeasureTime frameDescription
Serum lipids1 monthChange in fasting serum lipids
insulin secretion in response to mixed meal test1 monthChange in serum C-peptide profile during a mixed meal test at baseline and after one month intervention
Insulin sensitivity1 monthChange in mixed meal derived insulin sensitivity
Liver enzymes1 monthChange in serum alanine amino transferase

Countries

Cameroon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026